Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SVRA Stock Summary
Top 10 Correlated ETFs
SVRA
In the News
3 stocks to turn $100 into $1,000 in 2024
The previous year was prosperous for many investors, resulting in significant gains in the stock market. The outlook for 2024 seems promising, especially in the technology sector.
Savara to Present at Two Upcoming Healthcare Conferences
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences: Guggenheim 6th Annual Biotechnology Conference February 7, 2024 at 8:30am PT/ 11:30am ET Fireside Chat St. Regis Hotel, New York City, NY Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 at 7:40am PT / 10:40am ET Co.
3 Penny Stocks to Provide 1,000% Returns Over the Next Decade
While penny stocks promise substantial potential gains, the reality is that sub-$5 stocks are among the riskiest investments. Their low price often reflects underlying issues like weak business models, high debt, dwindling market share, and uncertain prospects.
The 3 Best Penny Stocks to Buy Now: September 2023
A new month arrives and with it comes new investment opportunities. We will not always need such a large capital to make our investments, for these penny stocks present us with good opportunities that we can take advantage of, with little capital but perhaps with great returns.
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm PT. A live webcast of the presentation will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clin.
Savara: A Speculative Play
Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed for a rare affliction that has no approved therapies and has a pivotal readout coming up in the second quarter of 2024. An update investment analysis around Savara follows in the paragraphs below.
Savara to Present at the Jefferies Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT. A live webcast of the fireside chat will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical s.
Why Shares of Savara Jumped on Tuesday
Savara is a clinical-stage pharmaceutical company with no revenue. The company expects a top-line readout on molgramostim in the second quarter of 2024.
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 1:20pm ET. A live webcast of the presentation will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
Why Shares of Savara Soared This Week
The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.
SVRA Financial details
SVRA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -2.62 | -0.86 | -0.34 | -0.25 | -0.33 | |
Operating cash flow per share | -1.13 | -0.67 | -0.3 | -0.23 | -0.31 | |
Free cash flow per share | -1.13 | -0.73 | -0.3 | -0.23 | -0.31 | |
Cash per share | 3.04 | 1.39 | 1.2 | 0.82 | 0.98 | |
Book value per share | 2.54 | 1.09 | 1.08 | 0.71 | 0.85 | |
Tangible book value per share | 2.26 | 0.88 | 0.99 | 0.64 | 0.78 | |
Share holders equity per share | 2.54 | 1.09 | 1.08 | 0.71 | 0.85 | |
Interest debt per share | 0.64 | 0.45 | 0.21 | 0.17 | 0.16 | |
Market cap | 179.32M | 68.21M | 166.06M | 236.8M | 776.46M | |
Enterprise value | 155.07M | 70.61M | 157.84M | 210.84M | 776.61M | |
P/E ratio | -1.71 | -1.33 | -3.67 | -6.08 | -14.2 | |
Price to sales ratio | 0 | 265.39 | 0 | 0 | 0 | |
POCF ratio | -3.97 | -1.71 | -4.14 | -6.85 | -15.21 | |
PFCF ratio | -3.96 | -1.58 | -4.14 | -6.85 | -15.12 | |
P/B Ratio | 1.76 | 1.06 | 1.15 | 2.2 | 5.53 | |
PTB ratio | 1.76 | 1.06 | 1.15 | 2.2 | 5.53 | |
EV to sales | 0 | 274.74 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -6.2 | -1.48 | -3.92 | -5.57 | -12.98 | |
EV to operating cash flow | -3.44 | -1.77 | -3.94 | -6.1 | -15.21 | |
EV to free cash flow | -3.43 | -1.64 | -3.93 | -6.1 | -15.12 | |
Earnings yield | -0.59 | -0.75 | -0.27 | -0.16 | -0.07 | |
Free cash flow yield | -0.25 | -0.63 | -0.24 | -0.15 | -0.07 | |
Debt to equity | 0.25 | 0.39 | 0.18 | 0.24 | 0.19 | |
Debt to assets | 0.19 | 0.26 | 0.15 | 0.19 | 0.15 | |
Net debt to EBITDA | 0.97 | -0.05 | 0.2 | 0.69 | 0 | |
Current ratio | 11.4 | 10.41 | 11.26 | 21.98 | 15.66 | |
Interest coverage | 1.13K | -33.27 | -18.18 | -441.35 | 0 | |
Income quality | 0.58 | 0.8 | 0.93 | 0.91 | 0.93 | |
Dividend Yield | 0 | 0.03 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.04 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 55.5 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 136.33 | 0 | 0 | 0 | |
Intangibles to total assets | 0.08 | 0.12 | 0.06 | 0.08 | 0.06 | |
Capex to operating cash flow | 0 | 0.08 | 0 | 0 | 0.01 | |
Capex to revenue | 0 | -12.82 | 0 | 0 | 0 | |
Capex to depreciation | -0.15 | -4.75 | -0.16 | -0.05 | -1.69 | |
Stock based compensation to revenue | 0 | 19.87 | 0 | 0 | 0 | |
Graham number | 12.25 | 4.59 | 2.87 | 2.01 | 2.52 | |
ROIC | -0.83 | -0.57 | -0.26 | -0.3 | -0.36 | |
Return on tangible assets | -0.84 | -0.6 | -0.27 | -0.3 | -0.33 | |
Graham Net | 2.19 | 0.83 | 0.97 | 0.63 | 0.76 | |
Working capital | 113.19M | 76.95M | 150.34M | 123.09M | 155.35M | |
Tangible asset value | 90.59M | 52.17M | 133.22M | 97.12M | 129.41M | |
Net current asset value | 89.56M | 51.76M | 132.9M | 96.96M | 128.76M | |
Invested capital | 0.25 | 0.39 | 0.18 | 0.24 | 0.19 | |
Average receivables | 1.65M | 1.66M | 1.42M | 1.05M | 979.5K | |
Average payables | 3.64M | 3M | 2.02M | 1.39M | 2.42M | |
Average inventory | -808.5K | -1.66M | -1.42M | 454.5K | 1.03M | |
Days sales outstanding | 0 | 2.41K | 0 | 0 | 0 | |
Days payables outstanding | 1.23K | 27.03K | 1.44K | 2.92K | 7.31K | |
Days of inventory on hand | -584.36 | -17.66K | -1.14K | 4.49K | 0 | |
Receivables turnover | 0 | 0.15 | 0 | 0 | 0 | |
Payables turnover | 0.3 | 0.01 | 0.25 | 0.13 | 0.05 | |
Inventory turnover | -0.62 | -0.02 | -0.32 | 0.08 | 175K | |
ROE | -1.03 | -0.79 | -0.31 | -0.36 | -0.39 | |
Capex per share | 0 | -0.06 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.07 | -0.05 | -0.07 | -0.1 | -0.09 | |
Operating cash flow per share | -0.06 | -0.08 | -0.07 | -0.08 | -0.09 | |
Free cash flow per share | -0.06 | -0.08 | -0.07 | -0.08 | -0.09 | |
Cash per share | 0.82 | 0.75 | 0.69 | 1.02 | 0.9 | |
Book value per share | 0.71 | 0.64 | 0.57 | 0.89 | 0.78 | |
Tangible book value per share | 0.64 | 0.57 | 0.5 | 0.83 | 0.72 | |
Share holders equity per share | 0.71 | 0.64 | 0.57 | 0.89 | 0.78 | |
Interest debt per share | 0.17 | 0.18 | 0.18 | 0.17 | 0.15 | |
Market cap | 236.8M | 297.92M | 488.95M | 621.22M | 845.26M | |
Enterprise value | 210.84M | 290.15M | 492.48M | 619.95M | 845.42M | |
P/E ratio | -5.34 | -9.04 | -10.68 | -9.36 | -13.13 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -27.37 | -24.77 | -47.6 | -47.2 | -54.17 | |
PFCF ratio | -27.36 | -24.77 | -46.58 | -47.05 | -54.09 | |
P/B Ratio | 2.2 | 3.03 | 5.57 | 4.24 | 6.02 | |
PTB ratio | 2.2 | 3.03 | 5.57 | 4.24 | 6.02 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -19.5 | -22.53 | -40.39 | -34.41 | -48.13 | |
EV to operating cash flow | -24.37 | -24.13 | -47.94 | -47.11 | -54.18 | |
EV to free cash flow | -24.36 | -24.12 | -46.92 | -46.95 | -54.1 | |
Earnings yield | -0.05 | -0.03 | -0.02 | -0.03 | -0.02 | |
Free cash flow yield | -0.04 | -0.04 | -0.02 | -0.02 | -0.02 | |
Debt to equity | 0.24 | 0.27 | 0.3 | 0.18 | 0.19 | |
Debt to assets | 0.19 | 0.2 | 0.22 | 0.15 | 0.15 | |
Net debt to EBITDA | 2.4 | 0.6 | -0.29 | 0.07 | -0.01 | |
Current ratio | 21.98 | 23.9 | 18.33 | 18.98 | 15.66 | |
Interest coverage | 169.92 | -15.83 | -17.24 | -12.5 | 0 | |
Income quality | 0.84 | 1.14 | 0.9 | 0.79 | 0.97 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.08 | 0.08 | 0.09 | 0.06 | 0.06 | |
Capex to operating cash flow | 0 | 0 | 0.02 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.12 | -0.17 | -9.38 | -0.69 | -0.36 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.07 | 0.88 | 0.98 | 1.42 | 1.25 | |
ROIC | -0.09 | -0.08 | -0.1 | -0.1 | -0.11 | |
Return on tangible assets | -0.09 | -0.07 | -0.1 | -0.1 | -0.1 | |
Graham Net | 0.63 | 0.56 | 0.49 | 0.81 | 0.7 | |
Working capital | 123.09M | 112.7M | 102.02M | 161.13M | 155.35M | |
Tangible asset value | 97.12M | 87.44M | 76.93M | 136.05M | 129.41M | |
Net current asset value | 96.96M | 86.52M | 75.78M | 134.57M | 128.76M | |
Invested capital | 0.24 | 0.27 | 0.3 | 0.18 | 0.19 | |
Average receivables | 907.5K | 997K | 1.02M | 976K | 978K | |
Average payables | 1.11M | 1.45M | 2.04M | 2.86M | 3.36M | |
Average inventory | 1.03M | 1.81M | 1.57M | 1.15M | 366K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 2.86K | 6.16K | 9.38K | 4.6K | 4.78K | |
Days of inventory on hand | 4.4K | 6.15K | 5.85K | 1.05K | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.03 | 0.01 | 0.01 | 0.02 | 0.02 | |
Inventory turnover | 0.02 | 0.01 | 0.02 | 0.09 | 66K | |
ROE | -0.1 | -0.08 | -0.13 | -0.11 | -0.11 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
SVRA Frequently Asked Questions
What is Savara Inc. stock symbol ?
Savara Inc. is a US stock , located in Austin of Tx and trading under the symbol SVRA
What is Savara Inc. stock quote today ?
Savara Inc. stock price is $4.98 today.
Is Savara Inc. stock public?
Yes, Savara Inc. is a publicly traded company.